Preterm Delivery a Risk in Systemic Sclerosis PDF Print E-mail
Thursday, 05 January 2012 08:08
Taken from http://www.flickr.com/photos/thousand_birds/4482649498/ via creative commonsMany women with systemic sclerosis can have successful pregnancies, but the rates of preterm birth, low birth weight, and intrauterine growth restriction are approximately twice as high in these women compared to the general population of pregnant women, based on data from 109 pregnancies in 99 women with systemic sclerosis. The findings were published in December's Arthritis & Rheumatism.

Data from previous studies have suggested negative outcomes for pregnancies in women with systemic sclerosis (SSc), but these have been small case series or large database reviews that did not allow for the identification of individual patients, said Dr. Mara Taraborelli of Spedali Civili and University, Brescia, Italy, and colleagues.

In this prospective study, the researchers followed 99 women with SSc who had 109 pregnancies between 2000 and 2011. The women attended one of 25 participating research centers in Italy.

The average age at conception was 32 years, and most of the women were white. A total of 107 pregnancies were spontaneous, and 2 were achieved with assisted reproductive techniques.

Preterm deliveries were significantly more common in the SSc women, compared to the general obstetric population that served as a control group (25% vs. 12%, respectively). Severe preterm delivery (defined as delivery at less than 34 weeks) also was significantly more common in SSc women, compared to the controls (10% vs. 5%, respectively).

In addition, very low birth weight babies and cases of intrauterine growth restriction were significantly more common in the SSc women, compared to the controls (5% vs. 1%, respectively, and 6% vs. 1%, respectively).

The researchers found no increase in hypertensive disorders of pregnancy or spontaneous pregnancy losses in SSc women, compared to the general pregnant population.

"We observed a low rate of disease progression shortly after the end of pregnancy; this risk might be greater in aSCL-70 positive patients with recent-onset disease," the researchers noted. All four cases of internal organ disease evolution within 12 months after delivery occurred in women who were aSCL-70 positive, and 3 of 23 (13%) of women who were aSCL-70 positive whose disease had lasted less than 3 years had some disease progression after delivery.

A total of six newborns spent a median of 15 days in the intensive care unit. Of these, one was severely premature and died of multi-organ failure.

The study findings were limited by the use of retrospective analysis and the use of controls for only one year, but the results suggest that successful pregnancies are possible for SSc women despite the increased risks for poor maternal and fetal outcomes, with multidisciplinary management, the researchers said. However, pregnancy may not be advisable for patients with severe organ damage or recent onset of SSc, especially those who are antitopoisomerase positive, they added.

Source: Splete, H. (2012), "Preterm Delivery a Risk in Systemic Sclerosis", Family Practice News;


 
More articles :

» Unite Against Scleroderma 2014

For the fourth year running, we will be hosting our annual “Unite Against Scleroderma” Awareness Walk. Scheduled to start from 2:30pm, the Walk would be held on Saturday 3rd May, 2014 and cover one full lap around the Queen’s Park Savannah,...

» Rituximab for Scleroderma: Does Something Finally Work?

Kevin Deane, MDPosted: 03/10/2010Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle StudyDaoussis D, Liossis SN, Tsamandas AC, et al. Rheumatology (Oxford). 2010;49:271-280BackgroundMultiple drugs have been tried in...

» Juvenile Localized Scleroderma: Fewer Flares With Methotrexate

was an effective and well-tolerated treatment for in a randomized, double-blind, placebo-controlled trial involving 70 patients with active disease. At the end of the 12-month study, 31 of 46 patients randomized to receive methotrexate had...

» Cell Therapy Yields Promising Results For Scleroderma Treatment

Cytori Therapeutics, Inc. provided preliminary data from a study evaluating a potential treatment for Scleroderma based on the company's cell therapy. The investigator-funded, open-label, pilot study is being conducted on patients with Cutaneous...

» Aspirin, Simvastatin Not Effective for Pulmonary Arterial Hypertension

Neither aspirin nor simvastatin improved outcomes for patients with in a phase II safety and efficacy trial recently published online in and simultaneously presented at the annual meeting of the .The primary end point of 6-minute walk distance did...

» Primary Biliary Cirrhosis Associated with Systemic Sclerosis: Diagnostic and Clinical Challenges

Cristina Rigamonti, Dimitrios P. Bogdanos, Maria G.Mytilinaiou, Daniel S. Smyk, Eirini I. Rigopoulou, and Andrew K. BurroughsReceived 3 June 2011; Accepted 7 September 2011Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease...